New Adeno-Associated Virus Capsids for Gene Therapy
This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.
Original patent title: “Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor”
This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines. Granted to University of Pennsylvania in 2022 with 16 claims and 1 forward citation, and it is expected to expire in 2041.
Coverage
What does this patent actually cover?
This patent is about creating specialized tools for gene therapy. It claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → specific versions of adeno-associated virus (AAV) capsids, which are like protective shells for delivering genetic material. Specifically, it describes cultured host cells that contain engineered DNA (recombinant nucleic acid molecules) designed to produce these new AAV capsids, named AAVhu37. These DNA molecules also carry a gene that is not from AAV (a heterologous non-AAV sequence), intended for therapeutic use. The patent details how these engineered cells, when containing specific parts of the AAVhu37 capsid protein sequence (like vp1, vp2, or vp3) and a 'rep gene' (which helps the virus replicate), can be used to produce gene therapy vectors. For example, a cell might be engineered with a plasmid containing the DNA for the AAVhu37 vp1 capsid protein and a therapeutic gene, along with a rep gene from AAV2.
The gap
What does this patent NOT cover?
- Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →.
- Does not cover the use of these AAV vectors in a living organism, only in cultured host cells.
- Does not cover the rep gene being from a source other than AAV2 if claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 3, 6, or 9 is considered.
- Does not cover the recombinant nucleic acid molecule being something other than a plasmid.
- Does not cover the heterologous non-AAV sequence being identical to an AAV sequence.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The innovation lies in identifying and defining specific novel sequences for AAV capsid proteins (AAVhu37) that can be engineered into vectors for gene delivery. This allows for potentially more targeted or efficient delivery of therapeutic genes compared to previously known AAV types.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Research laboratories developing gene therapy vectors
Biotechnology companies creating new treatments for genetic diseases
Why it matters
The bigger picture
Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.
Filed
October 12, 2021
Granted
June 14, 2022
Market context
Who's building on this
Companies in this space
The University of Pennsylvania, through its inventors, is the originator of this technology. Companies in the gene therapy space, such as those focused on rare diseases or neurological disorders, would be the primary entities interested in building upon these novel AAV capsids for their therapeutic development pipelines.
Market impact
This patent, by providing new AAV capsid sequences, aims to expand the toolkit available for gene therapy development. Such innovations are critical for enabling the creation of next-generation therapies that can overcome limitations of existing vectors, potentially leading to new treatments for a wider range of diseases and improving patient outcomes.
Claim 1 — Plain English
What this patent covers
This patent is about creating specialized tools for gene therapy. It claims specific versions of adeno-associated virus (AAV) capsids, which are like protective shells for delivering genetic material. Specifically, it describes cultured host cells that contain engineered DNA (recombinant nucleic acid molecules) designed to produce these new AAV capsids, named AAVhu37. These DNA molecules also carry a gene that is not from AAV (a heterologous non-AAV sequence), intended for therapeutic use. The patent details how these engineered cells, when containing specific parts of the AAVhu37 capsid protein sequence (like vp1, vp2, or vp3) and a 'rep gene' (which helps the virus replicate), can be used to produce gene therapy vectors. For example, a cell might be engineered with a plasmid containing the DNA for the AAVhu37 vp1 capsid protein and a therapeutic gene, along with a rep gene from AAV2.
The clever bit
The innovation lies in identifying and defining specific novel sequences for AAV capsid proteins (AAVhu37) that can be engineered into vectors for gene delivery. This allows for potentially more targeted or efficient delivery of therapeutic genes compared to previously known AAV types.
What it does not cover
- Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.
- Does not cover the use of these AAV vectors in a living organism, only in cultured host cells.
- Does not cover the rep gene being from a source other than AAV2 if claim 3, 6, or 9 is considered.
- Does not cover the recombinant nucleic acid molecule being something other than a plasmid.
- Does not cover the heterologous non-AAV sequence being identical to an AAV sequence.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Moderate
Citation count
6/40
Early citations
Claim breadth
11/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
20/20
Major company or institution
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$176K – $562K
Midpoint $351K · 14.9 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
16 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Wilson, J. M., Alvira, M. R., Gao, G., & Vandenberghe, L. H. (2022). New Adeno-Associated Virus Capsids for Gene Therapy (U.S. Patent No. 11,357,868). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/11357868/adeno-associated-virus-aav-clades-sequences-vectors-containing-same-and-uses-the
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US11357868"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 11499167 · 2022 · University of Pennsylvania
Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10
US 12735721 · 2026
Engineered AAV Vectors for Targeted Gene Delivery to Specific Body Parts
US 12735723 · 2026
Treating Muscular Dystrophy with a Self-Complementary AAV Gene Therapy
US 12350368 · 2025 · Massachusetts Institute of Technology
Delivering Large Gene Editing Tools into Cells with Hybrid Virus-Lipid Packages
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does New Adeno-Associated Virus Capsids for Gene Therapy cover?
This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.
Who owns patent US 11357868?
University of Pennsylvania owns this patent, granted in 2022.
When does this patent expire?
This patent is expected to expire on October 12, 2041, when the invention enters the public domain.
What is patent US 11357868 cited by?
This patent has been cited by 1 later patents that build on its ideas.
What problem does this patent solve?
Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.
What does this patent NOT cover?
Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.
Same assignee
More from University of Pennsylvania
Patent monitoring




